Comparative Pharmacology
Head-to-head clinical analysis: CAPEX versus EPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPEX versus EPICORT.
CAPEX vs EPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Epicort is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects by binding to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
IV: 50 mg every 8 hours over 30 minutes.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Terminal half-life is 1.5–2 hours in adults; prolonged to 3–4 hours in severe hepatic impairment
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Renal (70% as unchanged drug and inactive metabolites), biliary/fecal (30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid